NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

Smith did a good job of pointing out some strong points we're so used to hearing about that we tend to forget how important they are:

1. DCVax has virtually zero toxicity and we've not hit the maximum tolerable dose

2. We are improving Direct dosing and can garner even better results in Phase 2 than we did in Phase 1 (which is the opposite of the normal trend with experimental drugs which tend to demonstrate weaker efficacy as you move from Phase 1 to Phase 2 to Phase 3).

3. Direct could be a strong candidate for approval on the basis of just the Phase 2 because we're helping terminal patients who have no other viable options. This could even happen if as few as a 1/3 of patients see the kind of benefits we've witnessed in the case studies.

While his overall purpose seems to have been to lower expectations about the upcoming conference Smith reminded me why I am invested in this stock for the long haul.